Rahul Aras

Rahul Aras

Company: Iterion Therapeutics

Job title: President & CEO


Join me at Wnt


A Novel Downstream Therapeutic Target in the Wnt/β-Catenin Pathway 1:40 pm

• Discussing Tegavivint’s unique TBL-1 affinity and resulting oncogenic Wnt gene silencing without the toxicity of wider pathway disruption • Sharing the safety and clinical activity in Phase 1/2a clinical studies for Desmoid tumor patients • Guiding you through Iterion’s vision for wider clinical pursuits in other cancers involving nuclear β-catenin signaling, such as AML,…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.